What pharmacologic treatments are recommended for an adult with alcohol use disorder?

Treatment for Alcohol Use Disorder

For adults with alcohol use disorder, use naltrexone (50 mg/day orally) or acamprosate (666 mg three times daily) as first-line pharmacotherapy, combined with psychosocial interventions such as cognitive behavioral therapy or motivational interviewing. 1, 2

FDA-Approved First-Line Medications

The three FDA-approved medications for alcohol use disorder are naltrexone, acamprosate, and disulfiram 1:

Naltrexone (Preferred for Most Patients)

• Dosing: 50 mg/day orally or 380 mg monthly intramuscular injection
• Mechanism: Opioid receptor antagonist that reduces alcohol's rewarding effects
• Efficacy: Number needed to treat = 18 to prevent return to any drinking; NNT = 11 to prevent return to heavy drinking 1, 2
• Critical caveat: Causes hepatotoxicity - avoid in patients with liver disease 1, 3
• Injectable formulation reduces drinking days by approximately 5 days per month 2

Acamprosate (Safest for Liver Disease)

• Dosing: 666 mg three times daily (1,998 mg/day for patients ≥60 kg; reduce by one-third if <60 kg) 3
• Mechanism: NMDA receptor antagonist that reduces withdrawal effects and cravings
• Efficacy: Number needed to treat = 12 to prevent return to any drinking 1, 2
• Key advantage: No hepatic metabolism, no reported hepatotoxicity - safe in liver disease 1
• Start 3-7 days after last alcohol consumption, after withdrawal symptoms resolve 3

Disulfiram (Limited Use)

• Not recommended as first-line - causes acetaldehyde buildup leading to unpleasant reactions
• Contraindicated in patients with liver disease due to hepatotoxicity risk 1, 3

Algorithm for Medication Selection

Step 1: Assess for liver disease

• If liver disease present → Choose acamprosate (no hepatotoxicity) 1
• If no liver disease → Choose naltrexone (slightly better efficacy profile) 2

Step 2: Consider patient factors

• High motivation for aversive therapy → Consider disulfiram (only if no liver disease) 4
• Adherence concerns → Injectable naltrexone monthly may be preferable 2
• Renal dysfunction → Avoid acamprosate (renally excreted); choose naltrexone if liver function normal 1

Second-Line Medications (When First-Line Fails or Contraindicated)

Baclofen

• Dosing: 30-60 mg/day (10 mg three times daily)
• Only medication with RCT evidence in patients with cirrhosis - showed improved abstinence rates over 1 year 1
• Causes fewer dropouts than placebo 5
• Warning: May worsen mental status - exclude patients with hepatic encephalopathy 1

Gabapentin

• Dosing: 600-1,800 mg/day
• Renally excreted, no hepatic metabolism 1
• Monitor for renal dysfunction and sedation 1

Topiramate

• Dosing: 75-400 mg/day
• Reduces heavy drinking but causes more dropouts due to adverse effects 5
• Not studied in liver disease 1

Essential Psychosocial Interventions

Combine pharmacotherapy with behavioral treatment - this integrated approach is superior to either alone 1, 6:

Evidence-Based Modalities

• Cognitive behavioral therapy (CBT) - first-line behavioral intervention 1, 6
• Motivational interviewing - particularly effective for ambivalent patients 1
• Motivational enhancement therapy (MET) 1
• Alcoholics Anonymous and mutual aid societies 1
• Family/couples counseling 1

Key finding: CBT plus pharmacotherapy shows benefit over usual care plus pharmacotherapy, but CBT does not outperform other evidence-based therapies when combined with medication 6. The critical element is using any structured evidence-based therapy rather than nonspecific counseling.

Alcohol Withdrawal Management

For acute withdrawal syndrome, use benzodiazepines as gold standard 3, 7:

Benzodiazepine Selection

• Long-acting (diazepam 5-10 mg every 6-8 hours, chlordiazepoxide 25-100 mg every 4-6 hours): Better seizure/delirium protection 3, 7
• Short/intermediate-acting (lorazepam 1-4 mg every 4-8 hours): Safer in elderly and liver dysfunction 3, 7

Critical Supportive Care

• Thiamine 100-300 mg/day - give BEFORE glucose-containing IV fluids to prevent Wernicke encephalopathy 3
• Electrolyte replacement (especially magnesium) 3
• Carbamazepine 200 mg every 6-8 hours as benzodiazepine alternative for seizure prevention 3

Admission Criteria

Admit for inpatient treatment if: significant withdrawal symptoms, history of withdrawal seizures or delirium tremens, serious medical/psychiatric comorbidity, or outpatient treatment failure 3

Common Pitfalls to Avoid

1. Using naltrexone in liver disease - this causes hepatotoxicity and is contraindicated 1, 3, 7
2. Forgetting thiamine before glucose - can precipitate acute Wernicke encephalopathy 3
3. Using baclofen in hepatic encephalopathy - worsens mental status 1
4. Prescribing medication without behavioral therapy - combined treatment is significantly more effective 1, 6
5. Underdosing acamprosate - requires 666 mg three times daily for efficacy 1, 3

Treatment Duration

• Typical pharmacotherapy course: 3-6 months minimum, can extend to 12 months 3
• Acamprosate reaches therapeutic levels in 1-2 weeks 3
• Naltrexone: start 25 mg for 1-3 days, then increase to 50 mg 3